K Ray Chaudhuri, Maurizio F Facheris, Bruno Bergmans, Filip Bergquist, Susan R Criswell, Jia Jia, Pavnit Kukreja, Yohei Mukai, Amy M Spiegel, Resmi Gupta, Lars Bergmann, Rajesh Pahwa
{"title":"睡眠改善与福斯雷多巴/福斯卡比多巴改善生活质量和运动症状相关。","authors":"K Ray Chaudhuri, Maurizio F Facheris, Bruno Bergmans, Filip Bergquist, Susan R Criswell, Jia Jia, Pavnit Kukreja, Yohei Mukai, Amy M Spiegel, Resmi Gupta, Lars Bergmann, Rajesh Pahwa","doi":"10.1002/mdc3.14018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.</p><p><strong>Objectives: </strong>Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).</p><p><strong>Methods: </strong>Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and \"Off\"/\"On\" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score.</p><p><strong>Results: </strong>Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved \"Off\" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, \"Off\" time, QoL, and m-EDL.</p><p><strong>Conclusions: </strong>Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and \"Off\" time.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233834/pdf/","citationCount":"0","resultStr":"{\"title\":\"Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.\",\"authors\":\"K Ray Chaudhuri, Maurizio F Facheris, Bruno Bergmans, Filip Bergquist, Susan R Criswell, Jia Jia, Pavnit Kukreja, Yohei Mukai, Amy M Spiegel, Resmi Gupta, Lars Bergmann, Rajesh Pahwa\",\"doi\":\"10.1002/mdc3.14018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.</p><p><strong>Objectives: </strong>Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).</p><p><strong>Methods: </strong>Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and \\\"Off\\\"/\\\"On\\\" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score.</p><p><strong>Results: </strong>Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved \\\"Off\\\" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, \\\"Off\\\" time, QoL, and m-EDL.</p><p><strong>Conclusions: </strong>Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and \\\"Off\\\" time.</p>\",\"PeriodicalId\":19029,\"journal\":{\"name\":\"Movement Disorders Clinical Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233834/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Movement Disorders Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/mdc3.14018\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.14018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景福斯莱多巴/福斯卡比多巴是一种左旋多巴/卡比多巴原药的皮下注射剂：根据福斯莱多巴/福斯卡比多巴 3 期试验（NCT03781167）的中期数据，评估睡眠与疗效之间的相关性：计算睡眠（帕金森病睡眠量表-2 [PDSS-2]）与生活质量（QoL；帕金森病问卷-39）、日常生活运动体验（m-EDL；运动障碍协会-统一帕金森病量表第二部分）以及 "关"/"开 "时间之间的皮尔逊相关性，以了解基线和第26周的改善情况。回归分析对基线 PDSS-2 评分进行了调整：结果：基线睡眠与 QoL 有中度相关性（r = 0.44，P 结论：基线睡眠与 QoL 有中度相关性：使用磷左多巴/磷卡比多巴改善睡眠与改善 QoL 和 "关闭 "时间有关。
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.
Background: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.
Objectives: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).
Methods: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and "Off"/"On" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score.
Results: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved "Off" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, "Off" time, QoL, and m-EDL.
Conclusions: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and "Off" time.
期刊介绍：
Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
